Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism

原发性醛固酮增多症中醛固酮抑制试验的不一致性和不足之处

阅读:1

Abstract

BACKGROUND: The saline suppression test (SST) and the captopril challenge test (CCT) have traditionally been used to confirm or exclude primary aldosteronism (PA). New guidelines recommend using these tests to predict the likelihood of unilateral PA. This study evaluated the diagnostic accuracy, consistency, and clinical implications of these tests. METHODS: We conducted a retrospective study of 531 patients with high-probability features of PA who underwent both SST and CCT to evaluate their accuracy and ability to predict unilateral PA. Adrenal lateralization and surgical treatment decisions were guided by individualized clinical judgment rather than strictly relying on SST/CCT results. RESULTS: The rate of PA diagnosis ranged from 47.8% to 97.2% based on SST and CCT criteria. Discordance rates between SST and CCT ranged from 10.9% to 51.6%. In analyses restricted to only patients with clinically overt PA, where suppression testing is not considered necessary, the positivity rates of the SST and CCT were still suboptimal and test discordance persisted. Among patients with lateralizing PA, 6.6% to 27.9% had either a negative SST or CCT interpretation, and among those who achieved Primary Aldosteronism Surgical Outcome-defined biochemical cure after unilateral adrenalectomy, 4.1% to 39.8% had either a negative SST or CCT, and up to 5.1% had false-negative results on both tests. CONCLUSIONS: Well-established aldosterone suppression tests for PA demonstrated substantial inconsistency, false-negative interpretations, and the inability to reliably predict lateralization outcomes in PA. Aldosterone suppression testing, using SST and CCT, lack accuracy for the diagnosis and subtyping of PA in high-risk patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。